ACHILLES THERAPEUTICS PL-ADR (ACHL)

US00449L1026 - ADR

1.25  +0.06 (+5.04%)

After market: 1.27 +0.02 (+1.6%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ACHILLES THERAPEUTICS PL-ADR

NASDAQ:ACHL (3/28/2024, 8:00:00 PM)

After market: 1.27 +0.02 (+1.6%)

1.25

+0.06 (+5.04%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap50.98M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ACHL Daily chart

Company Profile

Achilles Therapeutics Plc is a biopharmaceutical company engages in developing transformative precision T-cell therapies to treat multiple types of solid tumors. The firm develops transformative precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. The company is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. The company refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.

Company Info

ACHILLES THERAPEUTICS PL-ADR

245 Hammersmith Road, Gunnels Wood Road

London W6 8PW

P: 442081544600

CEO: Iraj Ali

Employees: 234

Website: https://www.achillestx.com/

ACHL News

News Image2 months ago - Achilles Therapeutics PLCAchilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
News Image2 months ago - Achilles Therapeutics PLCAchilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference

LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered...

News Image3 months ago - Achilles Therapeutics PLCAchilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction

Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies

News Image3 months ago - Achilles Therapeutics PLCAchilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction

Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies...

News Image5 months ago - Achilles Therapeutics PLCAchilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
News Image5 months ago - Achilles Therapeutics PLCAchilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 –

ACHL Twits

Here you can normally see the latest stock twits on ACHL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example